drugset / Trial / NCT06081166

A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin

NCT06081166

Non-randomizedSequentialOpen-labelTreatment

Summary

A study to evaluate impact of Obicetrapib on PK levels of Atorvastatin and Rosuvastatin

Timeline

Start
2023-11-11
Primary completion
2023-12-02
Completion
2024-01-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin 80 mg Unknown 80 mg
Comparator Obicetrapib Small molecule 10 mg
Comparator Rosuvastatin 40 mg Unknown 40 mg

Indications

No indication recorded.